The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis

Clinics in Liver Disease

Volumn 16, Issue 3, 2012, Pages 487-504

  Pagadala, Mangesh R ^a   McCullough, Arthur J ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular morbidity; Fibrosis; Liver related mortality; Nonalcoholic steatohepatitis; Steatosis

Indexed keywords

APOPTOSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COMORBIDITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; END STAGE LIVER DISEASE; ENDOPLASMIC RETICULUM STRESS; FOLLOW UP; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MALLORY BODY; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; OXIDATIVE STRESS; PROGNOSIS; REVIEW; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME;

DISEASE PROGRESSION; FATTY LIVER; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MALLORY BODIES; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84864091966     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.05.006     Document Type: Review

References (78)

1. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40(6):1387-1395.
2. Luyckx F.H., Desaive C., Thiry A., et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998, 22(3):222-226.
3. Bambha K., Belt P., Abraham M., et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012, 55(3):769-780.
4. Williams C.D., Stengel J., Asike M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140(1):124-131.
5. McCullough A.J. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006, 40(Suppl 1):S17-S29.
6. Charlton M.R., Burns J.M., Pedersen R.A., et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011, 141(4):1249-1253.
7. Hashimoto E., Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic?. Hepatol Res 2012, 42(1):1-14.
8. Pagadala M., Dasarathy S., Eghtesad B., et al. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl 2009, 15(12):1662-1670.
9. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010, 363(14):1341-1350.
10. Wieckowska A., Feldstein A.E. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis 2008, 28(4):386-395.
11. Adams L.A., Angulo P. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis 2007, 11(1):25-35. viii.
12. Janiec D.J., Jacobson E.R., Freeth A., et al. Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes Surg 2005, 15(4):497-501.
13. Merriman R.B., Ferrell L.D., Patti M.G., et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006, 44(4):874-880.
14. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44(4):865-873.
15. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116(6):1413-1419.
16. Rafiq N., Bai C., Fang Y., et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009, 7(2):234-238.
17. Younossi Z.M., Stepanova M., Rafiq N., et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011, 53(6):1874-1882.
18. Feldstein A.E., Charatcharoenwitthaya P., Treeprasertsuk S., et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009, 58(11):1538-1544.
19. Jepsen P., Vilstrup H., Mellemkjaer L., et al. Prognosis of patients with a diagnosis of fatty liver-a registry-based cohort study. Hepatogastroenterology 2003, 50(54):2101-2104.
20. Dam-Larsen S., Becker U., Franzmann M.B., et al. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol 2009, 44(10):1236-1243.
21. Musso G., Gambino R., Cassader M., et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011, 43(8):617-649.
22. Angulo P., Keach J.C., Batts K.P., et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30(6):1356-1362.
23. Adams L.A., Sanderson S., Lindor K.D., et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005, 42(1):132-138.
24. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41(6):1313-1321.
25. Ludwig J., Viggiano T.R., McGill D.B., et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980, 55(7):434-438.
26. Mendler M.H., Kanel G., Govindarajan S. Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease. Liver Int 2005, 25(2):294-304.
27. Brunt E.M., Janney C.G., Di Bisceglie A.M., et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94(9):2467-2474.
28. Younossi Z.M., Gramlich T., Liu Y.C., et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998, 11(6):560-565.
29. Adams L.A., Feldstein A.E. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. J Dig Dis 2011, 12(1):10-16.
30. Malhi H., Gores G.J., Lemasters J.J. Apoptosis and necrosis in the liver: a tale of two deaths?. Hepatology 2006, 43(2 Suppl 1):S31-S44.
31. Lackner C., Gogg-Kamerer M., Zatloukal K., et al. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol 2008, 48(5):821-828.
32. Brunt E.M., Kleiner D.E., Wilson L.A., et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011, 53(3):810-820.
33. Fukusato T., Fukushima J., Shiga J., et al. Interobserver variation in the histopathological assessment of nonalcoholic steatohepatitis. Hepatol Res 2005, 33(2):122-127.
34. Ratziu V., Charlotte F., Heurtier A., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128(7):1898-1906.
35. Zatloukal K., French S.W., Stumptner C., et al. From Mallory to Mallory-Denk bodies: what, how and why?. Exp Cell Res 2007, 313(10):2033-2049.
36. Zhong B., Strnad P., Selmi C., et al. Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity. Hepatology 2009, 50(2):546-554.
37. Rakoski M.O., Brown M.B., Fontana R.J., et al. Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011, 9(10):902-909.e1.
38. Omary M.B., Ku N.O., Strnad P., et al. Toward unraveling the complexity of simple epithelial keratins in human disease. J Clin Invest 2009, 119(7):1794-1805.
39. Hanada S., Strnad P., Brunt E.M., et al. The genetic background modulates susceptibility to mouse liver Mallory-Denk body formation and liver injury. Hepatology 2008, 48(3):943-952.
40. Hanada S., Snider N.T., Brunt E.M., et al. Gender dimorphic formation of mouse Mallory-Denk bodies and the role of xenobiotic metabolism and oxidative stress. Gastroenterology 2010, 138(4):1607-1617.
41. Gramlich T., Kleiner D.E., McCullough A.J., et al. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol 2004, 35(2):196-199.
42. Cortez-Pinto H., Baptista A., Camilo M.E., et al. Nonalcoholic steatohepatitis-a long-term follow-up study: comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 2003, 48(10):1909-1913.
43. Feldstein A.E., Wieckowska A., Lopez A.R., et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50(4):1072-1078.
44. Machado M.V., Cortez-Pinto H. Cell death and nonalcoholic steatohepatitis: where is ballooning relevant?. Expert Rev Gastroenterol Hepatol 2011, 5(2):213-222.
45. Soderberg C., Stal P., Askling J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010, 51(2):595-602.
46. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129(1):113-121.
47. Haring R., Wallaschofski H., Nauck M., et al. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009, 50(5):1403-1411.
48. Calori G., Lattuada G., Ragogna F., et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011, 54(1):145-152.
49. Lazo M., Hernaez R., Bonekamp S., et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011, 343:d6891.
50. Angulo P., Alba L.M., Petrovic L.M., et al. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004, 41(6):943-949.
51. Adams L.A., Harmsen S., St Sauver J.L., et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010, 105(7):1567-1573.
52. Teli M.R., James O.F., Burt A.D., et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22(6):1714-1719.
53. Sanyal A.J., Banas C., Sargeant C., et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006, 43(4):682-689.
54. Yatsuji S., Hashimoto E., Tobari M., et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009, 24(2):248-254.
55. Hui J.M., Kench J.G., Chitturi S., et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003, 38(2):420-427.
56. Bhala N., Angulo P., van der Poorten D., et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011, 54(4):1208-1216.
57. Treeprasertsuk S., Leverage S., Adams L.A., et al. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 2012, 32(6):945-950.
58. Stepanova M., Younossi Z.M. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012, 10(6):646-650.
59. Ong J.P., Pitts A., Younossi Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008, 49(4):608-612.
60. Chen C.H., Nien C.K., Yang C.C., et al. Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig Dis Sci 2010, 55(6):1752-1760.
61. Wong V.W., Wong G.L., Yip G.W., et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011, 60(12):1721-1727.
62. Domanski J.P., Park S.J., Harrison S.A. Cardiovascular disease and nonalcoholic Fatty liver disease: does histologic severity matter?. J Clin Gastroenterol 2012, 46(5):427-430.
63. Targher G., Bertolini L., Padovani R., et al. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 2006, 23(4):403-409.
64. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43(2 Suppl 1):S99-S112.
65. Rinella M.E. Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease?. Hepatology 2011, 54(4):1118-1120.
66. Roberts M.S., Angus D.C., Bryce C.L., et al. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl 2004, 10(7):886-897.
67. Laish I., Braun M., Mor E., et al. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl 2011, 17(1):15-22.
68. Malik S.M., Devera M.E., Fontes P., et al. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl 2009, 15(12):1843-1851.
69. Bhagat V., Mindikoglu A.L., Nudo C.G., et al. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl 2009, 15(12):1814-1820.
70. Afzali A., Berry K., Ioannou G.N. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl 2012, 18(1):29-37.
71. Malik S.M., deVera M.E., Fontes P., et al. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant 2009, 9(4):782-793.
72. Brunt E.M., Kleiner D.E., Behling C., et al. Misuse of scoring systems. Hepatology 2011, 54(1):369-370. [author reply: 370-1].
73. Promrat K., Lutchman G., Uwaifo G.I., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39(1):188-196.
74. Vuppalanchi R., Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009, 49(1):306-317.
75. Piccinino F., Sagnelli E., Pasquale G., et al. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986, 2(2):165-173.
76. Sanyal A.J., Brunt E.M., Kleiner D.E., et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011, 54(1):344-353.
77. Goldstein N.S., Hastah F., Galan M.V., et al. Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens. Am J Clin Pathol 2005, 123(3):382-387.
78. Arun J., Jhala N., Lazenby A.J., et al. Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass. Obes Surg 2007, 17(2):155-161.